NewsEvents

Your Yourlocation: Home > Effects of low-dose theophylline combined with tiotropium bromide(136310-93-5) on lung function and quality of life in patients with mild to moderate stable chronic obstructive pulmonary disease

To observe the effects of low-dose theophylline combined with tiotropium bromide(136310-93-5) on pulmonary function and quality of life in patients with mild to moderate chronic obstructive pulmonary disease (COPD) and safety evaluation. Methods: 115 patients with mild to moderate COPD were divided into tiotropium group (37 cases), sustained release theophylline group (40 cases) and sustained release theophylline + tiotropium group according to the random number table method 38 cases), 38 patients with non-cardiopulmonary disease were selected as the control group. The observation period is 12 months. 6MWD and quality of life [improved British Medical Research Council Respiratory Difficulty Scale (mMRC) and COPD Assessment Test (CAT)] were measured before and 12 months after treatment. Results: 107 patients with COPD were followed up for 12 months. The tiotropium group, sustained release theophylline group, sustained release theophylline + tiotropium group were 35,36,36 cases. Tiotropium bromide(136310-93-5) group, sustained-release theophylline group, sustained-release theophylline + tiotropium group 6MWD before and after treatment no significant change. The frequency of short-acting bronchodilator drugs was the lowest in the sustained-release theophylline + tiotropium group (only 2.3 ± 1.4) times /week; 14 patients in the sustained-release theophylline had COPD acute during the 12-month treatment (9.96 ± 2.25) d (7.85 ± 2.51) and (8.29 ± 2.24) d], the difference was statistically significant (P <0.05), and the duration was significantly higher than that in tiotropium group (P <0.05). CONCLUSIONS: Long-term low-dose sustained-release theophylline monotherapy can not significantly improve the airflow restriction and quality of life in patients with mild to moderate COPD, and is more suitable as a drug for combination therapy. Tiotropium bromide(136310-93-5) treatment may be a cost-effective option for mild to moderate stable COPD therapy.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved